Elevation Oncology Inc
North American company
Times are shown in GMT-4, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
Latest ELEV News
Currently there are no news & analysis articles for this instrument. Visit our news hub for the latest investment news from ii and Alliance News